AstraZeneca and MSD hail progress in tackling hard-to-treat cancers
Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...
AstraZeneca stock drops after lung cancer drug trial setback
London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...
STAT6d
AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study
If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated ...
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
FiercePharma4d
AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune disease
Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart ... Some other key metrics favored AZ’s medicine.
AstraZeneca (LSE:AZN) Gains FDA Approval for Fasenra in EGPA, Boosting Revenue Growth and Market Position
AstraZeneca (LSE:AZN) is navigating a period of robust growth and strategic challenges. Recent developments include an 18% ...
AstraZeneca Shares Set For Worst Week in 14 Months on Sell Calls
AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...
FiercePharma7d
ESMO: AstraZeneca's Imfinzi extends life in bladder cancer type. Will FDA push back on its perioperative trial design?
AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...
Yahoo Finance3d
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
AstraZeneca’s Fasenra (benralizumab ... “This trial demonstrates that a biologic medicine given in a single monthly injection ...
Pharmabiz3d
US FDA approves AstraZeneca’s Fasenra to treat eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...
Daily1d
AstraZeneca FluMist gets USFDA nod for self-administered influenza vaccine
AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...
AstraZeneca PLC: FluMist approved for self-administration in US
FluMist approved for self-administration in the US Only influenza vaccine approved for self- or caregiver-administration at home, expanding options for influenza protection FluMist ...